Inventor · disambiguated record
Cassian Yee
Also filed as: YEE CASSIAN
16 granted patents·28 pending applications·14 citations·filing 2005–2025
88Inventor score
Files withUNIV TEXAS26YEE CASSIAN6HUTCHINSON FRED CANCER RES4THE FRED HUTCHINSON CANCER RES CENTER3NKMAX CO LTD2
Top patents by PatentIndex Score
44 records- 0183US9938498B2Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cellsNKMAX CO LTD·Filed 2013·Granted Apr 10, 2018·4 cites·5 claims
- 0283US9809797B2Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppressionYEE CASSIAN·Filed 2008·Granted Nov 7, 2017·5 cites·7 claims
- 0380US11098284B2Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppressionTHE FRED HUTCHINSON CANCER RES CENTER·Filed 2018·Granted Aug 24, 2021·1 cites·17 claims
- 0479US9951310B2Methods of using IL-21 for adoptive immunotherapy and identification of tumor antigensHUTCHINSON FRED CANCER RES·Filed 2014·Granted Apr 24, 2018·3 cites·14 claims
- 0578US2022204933A1Methods of using il-21 for adoptive immunotherapy and identification of tumor antigensHUTCHINSON FRED CANCER RES·Filed 2022·Application pending·0 cites
- 0676US10072246B2Enhanced generation of cytotoxic T lymphocytes by IL-21 mediated FoxP3 suppressionTHE FRED HUTCHINSON CANCER RES CENTER·Filed 2016·Granted Sep 11, 2018·1 cites·11 claims
- 0775US2025101079A1T cell receptors with mage-b2 specificity and uses thereofUNIV TEXAS·Filed 2024·Application pending·0 cites
- 0873US2025145953A1Use of histone modifiers to reprogram effector t cellsUNIV TEXAS·Filed 2024·Application pending·0 cites
- 0971US2024123007A1Hla-restricted vcx/y peptides and t cell receptors and use thereofUNIV TEXAS·Filed 2023·Application pending·0 cites
- 1069US11052140B2Methods of treatment using conditional superagonist CTL ligands for the promotion of tumor-specific CTL responsesYEE CASSIAN·Filed 2019·Granted Jul 6, 2021·0 cites·20 claims
- 1168US11306289B2Methods of using IL-21 for adoptive immunotherapy and identification of tumor antigensHUTCHINSON FRED CANCER RES·Filed 2018·Granted Apr 19, 2022·0 cites·9 claims
- 1268US2022073879A1Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppressionTHE FRED HUTCHINSON CANCER RES CENTER·Filed 2021·Application pending·0 cites
- 1368US2025090560A1T cell receptors for immunotherapyUNIV TEXAS·Filed 2024·Application pending·0 cites
- 1467US2010310533A1Methods of using il-21 for adoptive immunotherapy and identification of tumor antigensZYMOGENETICS INC·Filed 2009·Application pending·0 cites
- 1564US12202877B2T cell receptors with mage-B2 specificity and uses thereofUNIV TEXAS·Filed 2019·Granted Jan 21, 2025·0 cites·18 claims
- 1664US12173317B2Use of histone modifiers to reprogram effector T cellsUNIV TEXAS·Filed 2019·Granted Dec 24, 2024·0 cites·23 claims
- 1764US11696933B2HLA-restricted VCX/Y peptides and T cell receptors and use thereofUNIV TEXAS·Filed 2017·Granted Jul 11, 2023·0 cites·34 claims
- 1862US12319740B2Methods for production of tissue resident memory-like T cells and use thereofUNIV TEXAS·Filed 2019·Granted Jun 3, 2025·0 cites·18 claims
- 1959US2025289866A1Peptides and engineered t cell receptors targeting ndc80 antigen and methods of useUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2059US2025073333A1Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of useUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2158US2024207406A1Methods and compositions comprising mhc class i peptidesUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2257US10328135B2Method of obtaining cytolytic T cells by using mutant tumor epitopesYEE CASSIAN·Filed 2016·Granted Jun 25, 2019·0 cites·22 claims
- 2357US9314516B2Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responsesYEE CASSIAN·Filed 2011·Granted Apr 19, 2016·0 cites·15 claims
- 2457US2024009241A1Engineered t cell receptors targeting egfr antigens and methods of useUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2556US2025320306A1Methods for production of tissue resident memory-like t cells and use thereofUNIV TEXAS·Filed 2025·Application pending·0 cites
- 2656US2024293459A1Peptides and engineered t cell receptors targeting sars-cov-2 antigens and methods of useYEE CASSIAN·Filed 2022·Application pending·0 cites
- 2755US12178787B2T cell receptors for immunotherapyUNIV TEXAS·Filed 2018·Granted Dec 31, 2024·0 cites·20 claims
- 2855US2024024438A1Methods and compositions comprising mhc class peptidesUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2955US2006269973A1Methods of using IL-21 for adoptive immunotherapy and identification of tumor antigensYEE CASSIAN·Filed 2005·Application pending·0 cites
- 3054US2023227526A1Engineered t cell receptors and methods of useUNIV TEXAS·Filed 2021·Application pending·0 cites
- 3154US2023190812A1Engineered t cell receptors and methods of useUNIV TEXAS·Filed 2021·Application pending·0 cites
- 3253US2023143031A1Engineered t cell receptors and methods of useUNIV TEXAS·Filed 2021·Application pending·0 cites
- 3353US2021170002A1Slc45a2 peptides for immunotherapyUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3452US2016193369A1Magnetic nanoparticle and method for imaging t cellsUNIV WASHINGTON·Filed 2016·Application pending·0 cites
- 3552US2018223257A1Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cellsNKMAX CO LTD·Filed 2018·Application pending·0 cites
- 3651US2022372092A1Hla-restricted vcx/y peptides and t cell receptors and use thereofUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3751US2022347279A1Vcx/y peptides and use thereofUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3851US2023106973A1Methods for expansion of tumor infiltrating lymphocytes and use thereofUNIV TEXAS·Filed 2021·Application pending·0 cites
- 3950US12435310B2Expansion culture method for human-derived natural killer cells by using HDAC inhibitorUNIV KOREA RES & BUS FOUND·Filed 2019·Granted Oct 7, 2025·0 cites·1 claims
- 4050US2022409711A1Hla restricted hormad1 t cell receptors and uses thereofUNIV TEXAS·Filed 2020·Application pending·0 cites
- 4150US2011250146A1Magnetic nanoparticle and method for imaging t cellsHUTCHINSON FRED CANCER RES·Filed 2010·Application pending·0 cites
- 4250US2024197782A1Methods and compositions for genetic modification and therapeutic use of immune cellsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 4347US11684657B2HLA-restricted VGLL1 peptides and use thereof in promoting an immune response in a subjectUNIV TEXAS·Filed 2017·Granted Jun 27, 2023·0 cites·17 claims
- 4447US2019169262A1Slc45a2 peptides for immunotherapyUNIV TEXAS·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Cassian Yee files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →